XIAOMI-W
01810
BYD COMPANY
01211
POP MART
09992
4
BABA-W
09988
5
TENCENT
00700
HK Stock MarketDetailed Quotes
02197 CLOVER BIO-B
- 0.199
- -0.004-1.97%
Market Closed May 9 16:08 CST
258.12MMarket Cap-0.26P/E (TTM)
0.199High0.195Low567.00KVolume0.199Open0.203Pre Close112.24KTurnover0.04%Turnover RatioLossP/E (Static)1.30BShares0.58052wk High-0.15P/B258.12MFloat Cap0.18552wk Low--Dividend TTM1.30BShs Float14.800Historical High--Dividend LFY1.97%Amplitude0.185Historical Low0.197Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
CLOVER BIO-B News
CLOVER BIO-B: 2024 Annual Report
Three Leaf Clover Biotech-B (02197.HK) granted 5.964 million stock options and 9.0165 million restricted share units.
On April 2, Glonghui reported that Clover Biologics-B (02197.HK) announced that the Board of Directors declared on April 2, 2025, that the company granted a total of 5,964,000 stock options and 9,016,500 restricted stock units to several eligible participants in accordance with the terms of the post-IPO stock option plan and the restricted stock unit plan.
Clover Biotech-B (02197) announced its annual performance, with a loss of 0.903 billion yuan for the year.
Clover Bio-B (02197) announced its annual results for the year ending December 31, 2024, with revenues of 3841...
Express News | Clover Biopharmaceuticals FY Net Income RMB -903.4 Million
Express News | Clover Biopharmaceuticals FY Revenue RMB 11.6 Million
CLOVER BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024
Clover Biotech-B (02197): The Global Vaccine Immunization Alliance has unilaterally terminated the pre-purchase agreement and requested the corresponding refund.
Clover Biotech-B (02197) issued an announcement regarding Clover Biopharmaceutical (Hong Kong) Limited (the company’s full...
Threeleaf Clover Biotech-B (02197.HK) announced that its RSV candidate vaccine SCB-1019 has received IND clinical trial approval from the USA and has initiated a clinical study for repeated administration.
On March 24, 2023, GSOM published an announcement that Clover Biopharmaceuticals-B (02197.HK) has received approval from the USA Food and Drug Administration (FDA) for the clinical application (IND) of its RSV candidate vaccine SCB-1019 (a bivalent RSV PreF - trimeric subunit candidate vaccine without an adjuvant, based on Clover Biopharmaceuticals Trimer-Tag protein trimerization vaccine development platform), and the Phase I clinical trial for evaluating the repeat dosing of this candidate vaccine has completed the initial enrollment of participants. The repeat dosing Phase I clinical trial being conducted in the USA has recruited up to 160 elderly subjects.
Express News | Clover Biopharmaceuticals - Rejects Gavi Alliance's Claim for $224 Million Repayment
Express News | Clover Biopharmaceuticals - Announces U.S. Ind Clearance and Initiation of Revaccination Clinical Study for Rsv Vaccine Candidate Scb-1019 by US FDA
Express News | Clover Biopharmaceuticals - Gavi Terminates Advance Purchase Agreement With Clover HK
CLOVER BIO-B: POSTPONEMENT OF BOARD MEETING DATE
Sancy Clover Bio-B (02197.HK) will hold a Board of Directors meeting on March 24 to consider and approve the annual performance.
Gelonghui, March 12丨Trifolium Biological-B (02197.HK) announced that the company will hold a Board of Directors meeting on March 24, 2025 (Monday) to consider and approve the annual performance for the year ending December 31, 2024, and its release, as well as to assess the payment of the final dividend.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Trifolium Bio-B (02197.HK) granted a total of 6.2045 million restricted share units.
On January 20, Glory Exchange announced that on January 20, 2025, the company granted a total of 6.2045 million restricted stock units to one qualified participant in accordance with the terms of the restricted stock unit plan. The restricted stock unit plan is part of the Group's incentive plan. The Board of Directors believes that granting restricted stock units will (i) reward the recipient for their contributions to the growth and development of the Group and provide incentives to retain them for contributing to the Group's continuous development and long-term Global Strategy goals; and (ii) allow the recipient to hold shares.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Adidas Consortium-B (02197) SCB-1019: The potential best in its class, reshaping the global RSV market landscape
With its unique Trimer-Tag technology platform, Clover Biopharmaceuticals' RSV candidate vaccine SCB-1019 is expected to be a potential best-in-class, reshaping the market landscape of RSV vaccines~
Hong Kong healthcare stocks receive attention from investors again, with Trifolium Biotech surging nearly 15%.
①What is the impact of medical insurance negotiations on pharmaceutical stocks? ②What are the reasons for the rise of Tri Clover Biopharmaceutical and Yimington Corporation?